Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease?

CONTEXT Azathioprine is frequently used in the treatment of Crohn's disease. A severe side effect is acute pancreatitis, which is specific for Crohn's disease. Autoantibodies against exocrine pancreas occur in about 30% of Crohn's disease cases but not in other inflammatory diseases. Pancreatic autoantibody positive Crohn's disease patients might have a low grade inflammation of the pancreas which may be aggravated by the introduction of azathioprine, resulting in clinically overt acute pancreatitis. OBJECTIVE We hypothesized that the presence of pancreatic autoantibodies in Crohn's disease patients is associated with the development of azathioprine-induced pancreatitis. PARTICIPANTS Eight patients with Crohn's disease and azathioprine-induced pancreatitis and 26 patients with Crohn's disease not using azathioprine. MAIN OUTCOME MEASURE Pancreatic autoantibodies were determined by a standardized immunofluorescence method. RESULTS Two out of 8 patients with azathioprine-induced pancreatitis were positive for pancreatic autoantibodies (25.0%), detectable in serum dilutions of 1:40 and 1:160, respectively. In the control group of Crohn's disease patients, two (7.7%) were positive in serum dilutions of 1:2. All positive samples had an extracellular fluorescence pattern. The difference in the prevalence of pancreatic autoantibodies was not statistically significant (P=0.229). CONCLUSIONS We could not confirm our hypothesis that most or all patients with azathioprine-induced pancreatitis were pancreatic autoantibody positive. The prevalence of pancreatic autoantibodies in the Crohn's disease patients in our group was lower than in previous reports.This study does not support an association between pancreatic autoantibodies and azathioprine-induced pancreatitis in Crohn's disease. However, this association should not be definitively excluded and larger, preferably prospective, studies are needed.

[1]  I. Nolte,et al.  Association of interleukin-1 receptor-associated kinase M (IRAK-M) and inflammatory bowel diseases , 2007, Scandinavian journal of gastroenterology.

[2]  E. Kouroumalis,et al.  Pancreatic Autoantibodies in Greek Patients with Inflammatory Bowel Disease , 2005, Digestive Diseases and Sciences.

[3]  S. Targan,et al.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. , 2005, Gastroenterology.

[4]  K. Saeian,et al.  Increased Rates of Early Adverse Reaction to Azathioprine in Patients with Crohn's Disease Compared to Autoimmune Hepatitis: A Tertiary Referral Center Experience , 2005, The American Journal of Gastroenterology.

[5]  C. Libersa,et al.  ITPA genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression , 2005, Gut.

[6]  F. Klebl,et al.  Association of antibodies to exocrine pancreas with subtypes of Crohn’s disease , 2005, European journal of gastroenterology & hepatology.

[7]  J. Colombel,et al.  Relevance of serologic studies in inflammatory bowel disease , 2004, Current gastroenterology reports.

[8]  K. Van Steen,et al.  Pancreatic Autoantibodies in Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[9]  R. Gearry,et al.  Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. , 2004, Pharmacogenetics.

[10]  J. J. Homan van der Heide,et al.  Increased incidence of azathioprine‐induced pancreatitis in Crohn's disease compared with other diseases , 2004, Alimentary pharmacology & therapeutics.

[11]  C. Lewis,et al.  Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). , 2004, Pharmacogenetics.

[12]  D. Podolsky,et al.  Inflammatory bowel disease. , 2002, The New England journal of medicine.

[13]  K. Decochez,et al.  Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: association with IA-2 and islet cell autoantibodies. , 2001, Diabetes care.

[14]  S. Targan,et al.  Colonic Bacteria Express an Ulcerative Colitis pANCA-Related Protein Epitope , 2000, Infection and Immunity.

[15]  P. Bingley,et al.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. , 1998, Diabetes.

[16]  S. Targan,et al.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.

[17]  H. Buhr,et al.  Effect of different immunosuppressive agents on acute pancreatitis: a comparative study in an improved animal model. , 1998, Transplantation.

[18]  S. Endres,et al.  Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. , 1998, Scandinavian journal of gastroenterology.

[19]  William D. Dupont,et al.  PS power and sample size program available for free on the internet , 1997 .

[20]  M. Relling,et al.  Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. , 1996, Pharmacogenetics.

[21]  M. Scheurlen,et al.  Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. , 1996, Journal of clinical gastroenterology.

[22]  F. Seibold,et al.  Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. , 1991, Gut.

[23]  M. Otte,et al.  [Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn's disease and ulcerative colitis]. , 2008, Deutsche medizinische Wochenschrift.